JP2004533250A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004533250A5 JP2004533250A5 JP2002592975A JP2002592975A JP2004533250A5 JP 2004533250 A5 JP2004533250 A5 JP 2004533250A5 JP 2002592975 A JP2002592975 A JP 2002592975A JP 2002592975 A JP2002592975 A JP 2002592975A JP 2004533250 A5 JP2004533250 A5 JP 2004533250A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- domain
- medicament
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 33
- 102000004169 proteins and genes Human genes 0.000 claims 26
- 108090000623 proteins and genes Proteins 0.000 claims 26
- 239000003814 drug Substances 0.000 claims 17
- 238000004519 manufacturing process Methods 0.000 claims 17
- 239000012636 effector Substances 0.000 claims 16
- 239000012639 bacterial effector Substances 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 108020004414 DNA Proteins 0.000 claims 10
- 210000002569 neuron Anatomy 0.000 claims 10
- 230000002401 inhibitory effect Effects 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 230000014509 gene expression Effects 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 230000002452 interceptive effect Effects 0.000 claims 5
- 230000003834 intracellular effect Effects 0.000 claims 5
- 230000010189 intracellular transport Effects 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 230000028327 secretion Effects 0.000 claims 5
- 239000012528 membrane Substances 0.000 claims 4
- 230000001737 promoting effect Effects 0.000 claims 4
- 230000027455 binding Effects 0.000 claims 3
- 231100001102 clostridial toxin Toxicity 0.000 claims 3
- 210000000172 cytosol Anatomy 0.000 claims 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 230000032823 cell division Effects 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000010837 receptor-mediated endocytosis Effects 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 230000005945 translocation Effects 0.000 claims 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 108010055044 Tetanus Toxin Proteins 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 210000002449 bone cell Anatomy 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 230000009134 cell regulation Effects 0.000 claims 1
- 210000003890 endocrine cell Anatomy 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 210000002907 exocrine cell Anatomy 0.000 claims 1
- 230000000799 fusogenic effect Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- 230000002147 killing effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000014493 regulation of gene expression Effects 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 210000002955 secretory cell Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000032258 transport Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0112687.9A GB0112687D0 (en) | 2001-05-24 | 2001-05-24 | Pharmaceutical use of secreted bacterial effector proteins |
| PCT/GB2002/002384 WO2002096467A2 (en) | 2001-05-24 | 2002-05-21 | Pharmaceutical use for secreted bacterial effector proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009202601A Division JP2009286794A (ja) | 2001-05-24 | 2009-09-02 | 分泌された細菌エフェクタータンパク質の薬学的使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004533250A JP2004533250A (ja) | 2004-11-04 |
| JP2004533250A5 true JP2004533250A5 (enExample) | 2005-12-22 |
Family
ID=9915236
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002592975A Pending JP2004533250A (ja) | 2001-05-24 | 2002-05-21 | 分泌された細菌エフェクタータンパク質の薬学的使用 |
| JP2009202601A Pending JP2009286794A (ja) | 2001-05-24 | 2009-09-02 | 分泌された細菌エフェクタータンパク質の薬学的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009202601A Pending JP2009286794A (ja) | 2001-05-24 | 2009-09-02 | 分泌された細菌エフェクタータンパク質の薬学的使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040208889A1 (enExample) |
| EP (1) | EP1390400A2 (enExample) |
| JP (2) | JP2004533250A (enExample) |
| CN (1) | CN100439394C (enExample) |
| AU (1) | AU2002256803B2 (enExample) |
| CA (1) | CA2448963A1 (enExample) |
| GB (1) | GB0112687D0 (enExample) |
| WO (1) | WO2002096467A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| US8012491B2 (en) * | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
| US7601351B1 (en) | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
| US6991789B2 (en) * | 2004-06-29 | 2006-01-31 | Allergas, Inc. | Methods of modulating intracellular degradation rates of toxins |
| DE102004035606A1 (de) * | 2004-07-22 | 2006-03-30 | Biotecon Therapeutics Gmbh | Carrier für Arzneimittel zur Gewinnung der oralen Bioverfügbarkeit |
| US20060068469A1 (en) * | 2004-08-17 | 2006-03-30 | Research Development Foundation | Bacterial vector systems |
| US20090092652A1 (en) * | 2004-08-20 | 2009-04-09 | Children's Medical Center Corporation | Method for the inhibition of angiogenesis or cancer using protective antigen related molecules |
| AU2006233929B2 (en) * | 2005-04-11 | 2012-05-31 | Yeda Research And Development Co.Ltd. | Chimeric proteins comprising Yersinia Yop, their preparation and pharmaceutical compositions containing them |
| DE102005019302A1 (de) * | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| EP2550366B1 (en) * | 2010-03-23 | 2014-11-12 | IMBA-Institut für Molekulare Biotechnologie GmbH | Methods for identifying inhibitors of the type iii secretion system |
| US20130273092A1 (en) * | 2010-10-22 | 2013-10-17 | Trudeau Institute | Uses of yersinia yope peptide, gene and subparts thereof as a plague vaccine component and assays for yersinia pestis-specific t cells |
| WO2012163289A1 (zh) | 2011-06-01 | 2012-12-06 | 厦门大学 | 包含白喉毒素无毒突变体crm197或其片段的融合蛋白 |
| US10633643B2 (en) * | 2015-05-15 | 2020-04-28 | Board Of Regents Of The University Of Nebraska | Engineered Clostridium botulinum toxin adapted to deliver molecules into selected cells |
| GB201609216D0 (en) | 2016-05-25 | 2016-07-06 | Evox Therapeutics And Isis Innovation Ltd | Exosomes comprising therapeutic polypeptides |
| US20210054033A1 (en) | 2018-01-25 | 2021-02-25 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents |
| WO2022087856A1 (zh) * | 2020-10-26 | 2022-05-05 | 南京吉芮康生物科技研究院有限公司 | 一种减毒沙门氏菌分泌表达rbd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2498192A2 (fr) * | 1981-01-22 | 1982-07-23 | Pasteur Institut | Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications |
| DE3369466D1 (en) * | 1982-05-12 | 1987-03-05 | Harvard College | Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof |
| US5668255A (en) * | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| DE69511860T2 (de) * | 1994-05-31 | 2000-02-10 | Allergan, Inc. | Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine |
| US5614191A (en) * | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| US5972899A (en) * | 1996-01-25 | 1999-10-26 | New York University | Apoptosis induced by Shigella IpaB |
| SE9702191D0 (sv) * | 1997-06-09 | 1997-06-09 | Sven Pettersson | Coposition and methods for the treatment of inflammatory dideases |
| US5965381A (en) | 1998-03-06 | 1999-10-12 | Ludwig Institute For Cancer Research | Delivery of proteins into eukaryotic cells with recombinant yersinia |
| US6485977B1 (en) * | 1999-09-13 | 2002-11-26 | Cornell Research Foundation, Inc. | Recombinant constructs and techniques for delivering to eucaryotic cells bacterial proteins that are secreted via type III secretion systems |
-
2001
- 2001-05-24 GB GBGB0112687.9A patent/GB0112687D0/en not_active Ceased
-
2002
- 2002-05-21 AU AU2002256803A patent/AU2002256803B2/en not_active Ceased
- 2002-05-21 CA CA002448963A patent/CA2448963A1/en not_active Abandoned
- 2002-05-21 WO PCT/GB2002/002384 patent/WO2002096467A2/en not_active Ceased
- 2002-05-21 EP EP02726319A patent/EP1390400A2/en not_active Withdrawn
- 2002-05-21 US US10/478,516 patent/US20040208889A1/en not_active Abandoned
- 2002-05-21 CN CNB028105052A patent/CN100439394C/zh not_active Expired - Fee Related
- 2002-05-21 JP JP2002592975A patent/JP2004533250A/ja active Pending
-
2009
- 2009-09-02 JP JP2009202601A patent/JP2009286794A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004533250A5 (enExample) | ||
| Kosikowska et al. | Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015) | |
| KR102139844B1 (ko) | 암 표적화 치료용 알부민-결합 아르기닌 데이미나제를 포함하는 약제학적 조성물 | |
| CN101675067B (zh) | 肽组合物的修饰以提高稳定性和递送效率 | |
| Fang et al. | Enhanced bacterial tumor delivery by modulating the EPR effect and therapeutic potential of Lactobacillus casei | |
| CA2482598A1 (en) | Peptide inhibitors of protein kinase c | |
| JP2009286794A (ja) | 分泌された細菌エフェクタータンパク質の薬学的使用 | |
| NZ606480A (en) | Albumin binding peptide-mediated disease targeting | |
| JP2020143084A (ja) | 治療目的のための抗体−ウレアーゼコンジュゲート | |
| KR20210057072A (ko) | 알파 코넥신 c-말단 펩타이드에 대한 나노 입자 제제 및 사용 방법 | |
| EP1523336B1 (en) | Targeted agents for nerve regeneration | |
| EP4100041A1 (en) | Treatment of panx1 associates diseases | |
| AU2002256803A1 (en) | Pharmaceutical use for secreted bacterial effector proteins | |
| BRPI1014631A2 (pt) | peptídeos e seus usos. | |
| WO2021046398A3 (en) | Combination antiviral therapy for measles | |
| Suk Choi et al. | Cell penetrating peptides for tumor targeting | |
| JP2016509997A (ja) | 骨粗鬆症を抑制するための治療 | |
| Sarfaraz et al. | Recent updates on peptide molecules in drug and vaccine development | |
| ES2682679T3 (es) | Supresión del picor | |
| JP6530768B2 (ja) | サイトカイン−キトサンバイオコンジュゲート及びその使用方法 | |
| WO2014020209A1 (es) | Uso de hidrolizados de proteínas lácteas como protectores a nivel gastrointestinal | |
| Fabbri et al. | Bacterial protein toxins: current and potential clinical use | |
| JP2003513941A (ja) | 溶菌毒素および毒素結合体の使用 | |
| US20050256040A1 (en) | Artificially designed pore-forming proteins with anti-tumor effects | |
| WO2024228904A3 (en) | Compositions and methods to enhance immune checkpoint blockade therapy against hypoxic tumors |